SCHEMBL2742672

SCHEMBL2742672

COc1ccc2c(c1OC)CN1CCc3cc(C)c(C)cc3[C@H]1C2

nearest known ligand 0.82

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 15/20 0.82
DRD2 P14416 12/20 0.82
DRD3 P35462 9/20 0.82
F3 P13726 6/20 0.82
DRD5 P21918 6/20 0.82
SIGMAR1 Q99720 4/20 0.82
CYP3A4 P08684 2/20 0.82
LMNA P02545 2/20 0.80
TSHR P16473 1/20 0.80
DRD4 P21917 3/20 0.76
ADRA1A P35348 2/20 0.72
CYP1A2 P05177 1/20 0.72
CYP2D6 P10635 1/20 0.72
CYP2C19 P33261 1/20 0.72
MEN1 O00255 1/20 0.72
KMT2A Q03164 1/20 0.72
HTR1A P08908 1/20 0.67
ADRA1D P25100 1/20 0.65
ADRA1B P35368 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12630242 1.00 DRD1 (0.82) DRD1DRD2DRD3F3DRD5
SCHEMBL20759563 0.94 DRD1 (0.84) DRD1DRD2DRD3F3DRD5
SCHEMBL18860957 0.91 DRD1 (0.85) DRD1DRD2DRD3F3DRD5
SCHEMBL13960236 0.91 DRD1 (0.85) DRD1DRD2DRD3F3DRD5
SCHEMBL2742673 0.91 DRD1 (0.85) DRD1DRD2DRD3F3DRD5
Tetrahydropalmatine SCHEMBL230850 0.90 DRD1 (1.00) DRD1DRD2DRD3F3DRD5
Tetrahydropalmatine SCHEMBL2742488 0.90 DRD1 (1.00) DRD1DRD2DRD3F3DRD5
Tetrahydropalmatine SCHEMBL29363068 0.90 DRD1 (1.00) DRD1DRD2DRD3F3DRD5
Tetrahydropalmatine SCHEMBL29689912 0.90 DRD1 (1.00) DRD1DRD2DRD3F3DRD5
Tetrahydropalmatine SCHEMBL29999115 0.90 DRD1 (1.00) DRD1DRD2DRD3F3DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815900-B2 Compounds and compositions for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2014-08-26 US disclosed
US-8710071-B2 Compounds, compositions and methods for reducing lipid levels CVI PHARMACEUTICALS LIMITED (KY) 2014-04-29 US disclosed
US-20120004223-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2012-01-05 US disclosed
US-20110269754-A1 COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2011-11-03 US disclosed
US-20110009628-A1 Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same CVI PHARMACEUTICALS LIMITED (KY) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009628-A1 Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same LIPC, LDLR, PCSK9 DRD1 4873/4885DRD2 4863/4885DRD3 4832/4885
US-20120004223-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS LIPC, LDLR, PCSK9 DRD1 4858/4885DRD2 4824/4885DRD3 4783/4885
US-20110269754-A1 COMPOUNDS AND COMPOSITIONS FOR REDUCING LIPID LEVELS LIPC, LIPE, BCHE DRD1 465/4885DRD2 139/4885DRD3 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.